Sugi Predict

Sugi Predict / Compounds / SCHEMBL20587999

SCHEMBL20587999

SCHEMBL20587999

O=C(O)c1conc1C1CCC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACMSD Q8TDX5 2/20 0.37
▸ HCAR2 Q8TDS4 1/20 0.37
▸ MAPT P10636 2/20 0.34
▸ TAS1R3 Q7RTX0 2/20 0.34
▸ TAS1R1 Q7RTX1 2/20 0.34
▸ TAS1R2 Q8TE23 2/20 0.34
▸ KDM5A P29375 1/20 0.33
▸ KDM5B Q9UGL1 1/20 0.33
▸ S1PR3 Q99500 2/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ GLA P06280 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ HIF1A Q16665 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ KMO O15229 1/20 0.33
▸ IKBKE Q14164 1/20 0.32
▸ TBK1 Q9UHD2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30281241 0.96 ACMSD (0.40) ACMSDHCAR2MAPTTAS1R3TAS1R1
SCHEMBL932926 0.93 MAPT (0.40) ACMSDHCAR2MAPTTAS1R3TAS1R1
SCHEMBL23990444 0.82 MAPT (0.31) MAPTTAS1R3TAS1R1TAS1R2CHRNA4
SCHEMBL30621073 0.79 KMT2A (0.42) ACMSDMAPTTAS1R3TAS1R1TAS1R2
SCHEMBL22207600 0.78 MAPT (0.32) MAPTS1PR3
SCHEMBL23062875 0.76 TAS1R3 (0.33) MAPTTAS1R3TAS1R1TAS1R2KDM4E
SCHEMBL20305332 0.72 LMNA (0.41) MAPTTAS1R3TAS1R1TAS1R2KDM4E
SCHEMBL23068842 0.72 EPHX2 (0.33) TAS1R3TAS1R1TAS1R2CHRNA4
SCHEMBL28565231 0.71 HCAR2 (0.37) ACMSDHCAR2TAS1R3TAS1R1TAS1R2
SCHEMBL12985873 0.69 HCAR2 (0.45) ACMSDHCAR2MAPTKDM5AKDM5B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4143195-B1 IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 JANSSEN PHARMACEUTICA NV (BE) 2025-05-21 — — EP disclosed
US-12024524-B2 Imidazopyridazines as modulators of IL-17 JANSSEN PHARMACEUTICA NV (BE) 2024-07-02 — — US disclosed
US-20230357254-A1 IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 JANSSEN PHARMACEUTICA NV (BE) 2023-11-09 — — US disclosed
US-11702422-B2 Imidazopyridazines as modulators of IL-17 JANSSEN PHARMACEUTICA NV (BE) 2023-07-18 — — US disclosed
CN-110769821-B Spiro indolines as IL-17 modulators UCB生物制药有限责任公司 2023-07-07 — — CN disclosed
US-11691979-B2 Imidazopyridazines as modulators of IL-17 JANSSEN PHARMACEUTICA NV (BE) 2023-07-04 — — US disclosed
US-20230081548-A1 IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 JANSSEN PHARMACEUTICA NV (BE) 2023-03-16 — — US disclosed
EP-4143195-A1 IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 Janssen Pharmaceutica NV (BE) 2023-03-08 — — EP disclosed
US-20220402922-A1 IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 JANSSEN RESEARCH & DEVELOPMENT, LLC 2022-12-22 — — US disclosed
EP-3638227-B1 SPIROCYCLIC INDOLINES AS IL-17 MODULATORS UCB Biopharma SRL (BE) 2022-08-10 — — EP disclosed
WO-2021222404-A1 IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 JANSSEN BIOTECH, INC. (US) 2021-11-04 — — WO disclosed
US-11052076-B2 Spirocyclic indolines as IL-17 modulators UCB Biopharma SRL (BE) 2021-07-06 — — US disclosed
US-20200138797-A1 Spirocyclic Indolines as IL-17 Modulators UCB Biopharma SRL (BE) 2020-05-07 — — US disclosed
EP-3638227-A1 SPIROCYCLIC INDOLINES AS IL-17 MODULATORS UCB Biopharma SRL (BE) 2020-04-22 — — EP disclosed
CN-110769821-A Spirocyclic indolines as IL-17 modulators UCB生物制药私人有限公司 2020-02-07 — — CN disclosed
WO-2018229079-A1 SPIROCYCLIC INDOLINES AS IL-17 MODULATORS UCB BIOPHARMA SPRL (BE) 2018-12-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11691979-B2 Imidazopyridazines as modulators of IL-17 IL17A, IL23R, IL15 ACMSD 3874/4885HCAR2 703/4885MAPT 3647/4885
US-20230357254-A1 IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 IL17A, IL23R, IL15 ACMSD 3874/4885HCAR2 703/4885MAPT 3647/4885
US-12024524-B2 Imidazopyridazines as modulators of IL-17 IL17A, IL23R, IL15 ACMSD 3874/4885HCAR2 703/4885MAPT 3647/4885
US-20230081548-A1 IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 IL17A, IL23R, IL15 ACMSD 3874/4885HCAR2 703/4885MAPT 3647/4885
US-20220402922-A1 IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 IL17A, IL23R, IL15 ACMSD 3874/4885HCAR2 703/4885MAPT 3647/4885
US-11052076-B2 Spirocyclic indolines as IL-17 modulators IL17A, IL2, IL18 ACMSD 4600/4885HCAR2 243/4885MAPT 2419/4885
US-20200138797-A1 Spirocyclic Indolines as IL-17 Modulators IL17A, IL2, IL18 ACMSD 4600/4885HCAR2 243/4885MAPT 2419/4885
US-11702422-B2 Imidazopyridazines as modulators of IL-17 IL17A, IL23R, IL15 ACMSD 3874/4885HCAR2 703/4885MAPT 3647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.